DIRS.INFO The most relevant business & tech news

☆ WeightWatchers could either win big or lose faithful customers, or both, in its pivot to Ozempic trend
▼ + stars: | 2023-07-22 | by ( Jordan Hart | ) www.businessinsider.com time to read: +3 min

Sequence offers access to weight-loss drugs like Ozempic and Wegovy. Analysts say the move could save the company, but some WeightWatchers members aren't happy. Although the medication has gained popularity online and among celebrities, veteran WeightWatchers members aren't all happy with the company's pivot. Some WeightWatchers members expressed concern that the company was abandoning its message of self-restraint for the easy solution of weight-loss medication. Sequence, meanwhile, prescribes weight-loss medications like Ozempic and Wegovy and helps patients afford the drugs through insurance and reimbursements.

Persons: WeightWatchers, aren't, They're, Goldman Sachs, Sima Sistani, Jenny Craig Organizations: WW, Inc, Bloomberg, Employers

☆ Goldman adds a utility stock to its list of elite picks for clients
▼ + stars: | 2023-07-03 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

As the third quarter and second half open, Goldman Sachs is adding a key utility stock to its high-conviction stock list. These are some of the other names that made the cut: Goldman views the potential launch of an iPhone 15 come September as a big potential catalyst for shares of Apple. Like its peers, Apple shares have been on a tear in 2023, surging roughly 49% in the first half as Wall Street bet on artificial intelligence and returned to tech after a terrible 2022. WW International is positioned for the most upside potential among all the stocks on Goldman's list, with a $13 price target implying that shares can nearly double. Other key names highlighted in the list include Amazon , Warner Bros Discovery , Merck and JPMorgan Chase .

Persons: Goldman Sachs, Goldman, Steven Kron, — CNBC's Michael Bloom Organizations: Southern Company, Atlanta, Apple, Warner Bros Discovery, Merck, JPMorgan Chase

☆ Jenny Craig is going out of business
▼ + stars: | 2023-05-05 | by ( Jordan Valinsky | ) edition.cnn.com time to read: +3 min

New York CNN —Jenny Craig, the weight-loss chain, has confirmed that it’s shutting down for good. Named after its founder, the Jenny Craig business started when she couldn’t lose weight after giving birth to her second child. WeightWatchers, for example, is getting into the prescription weight-loss drug business. The $106 million acquisition of Sequence will give WW a foothold into the growing market for prescription drugs to manage weight loss. Ozempic has gained popularity in part due to celebrities using it for weight loss.

☆ Jenny Craig is reportedly winding down its weight-loss centers and warning of mass layoffs
▼ + stars: | 2023-04-28 | by ( Nathaniel Meyersohn | ) edition.cnn.com time to read: +2 min

New York CNN —Jenny Craig is reportedly shutting down some of its weight-loss centers and warning employees of mass layoffs amid upheaval in the industry from popular new prescription drugs like Ozempic. Jenny Craig alerted employees to potential layoffs as it begins “winding down physical operations” and hunts for a buyer, according to NBC News. Jenny Craig has nearly 500 weight-loss centers in the United States and Canada. We will have more details to share in the coming weeks as our plans are solidified,” a spokesperson for Jenny Craig said in a statement to CNN. Ozempic has gained popularity in part due to celebrities using it for weight loss.

☆ Here are Tuesday's biggest analyst calls of the day: Apple, Amazon, UPS, Netflix, WW, Disney & more
▼ + stars: | 2023-04-11 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Morgan Stanley names UnitedHealth a top pick Morgan Stanley says the healthcare company is best positioned in a recession. Morgan Stanley reiterates Netflix as equal weight Morgan Stanley said Netflix is the "streaming winner" but that it's "priced as such." Morgan Stanley downgrades Nasdaq to equal weight from overweight Morgan Stanley said that it has growth concerns for the exchange operator. JPMorgan upgrades Federated Hermes to overweight from underweight JPMorgan said the rate environment makes the capital market company's stock more attractive. Morgan Stanley upgrades AstraZeneca to overweight from equal weight Morgan Stanley said the pharmaceutical company is "leading the race" to outsmart cancer.

☆ WeightWatchers' parent rockets higher by 25% after Goldman says the stock will more than triple
▼ + stars: | 2023-04-11 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

WW International , the parent WeightWatchers, could see its stock price more than triple as the diet company's new foray into obesity medications could result in a major turnaround, Goldman Sachs said. The Wall Street firm upgraded the stock to buy from neutral Monday evening and raised its 12-month price target to $13. The stock skyrocketed 28% in premarket trading Tuesday after closing Monday's trading at $4.12 apiece. Goldman turned bullish after WW acquired Sequence , a telehealth platform that provides its subscribers with access to GLP-1 medications such as Wegovy and Ozempic. "We believe a catalyst for a turnaround has emerged with its new obesity drug on-ramp solution," Goldman said.

Mohawk Industries — Shares of the flooring manufacturer gained 5% after Loop Capital upgraded the company to buy from its previous hold rating. WisdomTree — Shares of the financial firm gained 3% after the company said it had $1.9 billion of net flows in March. New York Community Bancorp — Shares of the regional bank gained 2.7% after Jefferies upgraded the stock to buy from hold. LendingClub — The lending stock gained 5% after JPMorgan initiated coverage of the stock at overweight. Murphy Oil — The natural gas company's shares gained 2.6% after Truist upgraded shares to buy from hold.

☆ Stocks making the biggest moves premarket: Moderna, CarMax, Whirlpool and more
▼ + stars: | 2023-04-11 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

CarMax — Shares of the vehicle retailer soared 7% on the back of better-than-expected quarterly earnings. Upstart — Upstart fell about 2% after JPMorgan initiated coverage of the lending stock with an underweight rating, citing a worsening environment for loans. Whirlpool — Shares gained more than 2% after Goldman Sachs upgraded Whirlpool to buy from neutral. LendingClub — The lending platform gained 4.8% after JPMorgan initiated coverage of the stock as overweight. Array Technologies — Shares of the solar technology company gained 2% after Wolfe Research initiated coverage of Array with an outperform rating.

☆ WeightWatchers Moves Into the Ozempic Market With Telehealth Deal
▼ + stars: | 2023-03-07 | by ( Andrea Petersen | ) www.wsj.com time to read: 1 min

WW, known for food-tracking and lifestyle changes, is moving to also offer customers a medical weight-loss approach. WW International Inc., known as WeightWatchers, is buying digital health company Sequence, marking the diet company’s move into the hot market for diabetes and obesity drugs including Ozempic and Wegovy. Sequence is a subscription service that offers telehealth visits with doctors who can prescribe the drugs. WeightWatchers, which has long promised to help customers lose weight through food-tracking and lifestyle changes, is moving to also offer customers a medical weight-loss approach.

☆ Stocks making the biggest moves midday: Rivian, Delta, Snap, Dish Network and more
▼ + stars: | 2023-03-07 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

United Airlines — United Airlines gained 4.4%, as the broader airline space got a boost after the Justice Department sued to block JetBlue's acquisition of American Airlines. Snap — The tech company's stock gained 4.1%, adding to the 13% it gained on Monday. Dish Network -- The stock climbed 7.4% after Dish co-founder and Executive Vice President James DeFranco disclosed the purchase of 1.45 million shares. DXC Technology — Shares fell 4.5% after DXC Technology said talks of a possible acquisition of the information technology company by a financial sponsor were terminated. Bank stocks — Bank stocks fell after Fed Chair Jerome Powell suggested that rates may need to go higher for longer.

☆ Top 10 things the Club is watching in the stock market Tuesday: Fed's Powell, Meta, obesity
▼ + stars: | 2023-03-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Meta Platforms ' (META) "year of efficiency" set to continue: Bloomberg is reporting job cuts in the thousands could happen as soon as this week. WW International (WW) is higher after announcing deal to acquire the anti-obesity-focused telehealth provider Sequence. (Jim Cramer's Charitable Trust is long META, LIN, CSCO, AMZN, LLY. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ WW International CEO on weight loss drugs: Still critical you make the right lifestyle changes
▼ + stars: | 2023-03-07 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWW International CEO on weight loss drugs: Still critical you make the right lifestyle changesCNBC's Meg Tirrell talks with Sima Sistani, WW International CEO, on 'Closing Bell: Overtime' to discuss the company's stock surge after announcing it had acquired Sequence, a telehealth platform that helps treat obesity.

☆ Stocks making the biggest premarket moves: Meta, Rivian, WW International, KeyCorp and more
▼ + stars: | 2023-03-07 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

WW International — Shares of company formerly known as Weight Watchers jumped as much as 17.6% in premarket trading after announcing a deal to acquire telehealth firm Sequence. The Wall Street firm said the aircraft's weight has raised questions and led him to wonder if the design is "overly aggressive." Its price target of $39 implies 24.5% upside from Monday's close. The Wall Street firm said there is a large unmet need for resistant hypertension treatment and said Mineralys has "potential best-in-class" data. The Wall Street firm said Hensai "outshines peers, with its superior scale and margin, and its strong project pipeline."

☆ Under threat, Weight Watchers enters obesity drug space. Here's what it means for the stock
▼ + stars: | 2023-03-07 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

The company's sales have been in a steady multiyear decline after an attempt to de-emphasize weight loss and focus on wellness failed miserably. WW 1Y mountain The parent of Weight Watchers has seen its market value shrink as sales have dropped for several years. Another drug, Eli Lilly's Mounjaro, adds a second incretin hormone to the mix and has been shown to be even more successful with weight loss. This trend could provide an opportunity for the core Weight Watchers brand and its focus on behavior modification. That scenario assumes Weight Watchers continues to see membership erosion, while cost controls help minimize margin compression.

☆ WeightWatchers stock surges 70% after company agrees to buy obesity treatment platform
▼ + stars: | 2023-03-07 | by ( Rebecca Picciotto | ) www.cnbc.com time to read: +1 min

Shares of WW International , also known as WeightWatchers, skyrocketed Tuesday after the company said it planned to buy Sequence, a telehealth platform that provides treatment for obesity. Shares of the company were down 57% over the past year as it struggled to pivot to wellness and move away from weight loss. Sistani took over as chief executive at the end of February, steering the company back toward weight loss messaging. The Sequence announcement comes as companies across the weight loss industry look to offer obesity medications as a pathway to customers looking to shed pounds. The trend has led to a shortage in medications like Ozempic, which are commonly prescribed for Type 2 diabetes.

☆ WeightWatchers jumps into into the prescription weight loss drug business with Ozempic
▼ + stars: | 2023-03-07 | by ( Nathaniel Meyersohn | ) edition.cnn.com time to read: +2 min

New York CNN —WeightWatchers is getting into the booming prescription weight loss drug business. The GLP-1 agonists Sequence helps prescribe include Wegovy, Ozempic, and Rybelsus. The FDA approved Ozempic for the management of diabetes in 2017 and Wegovy for weight loss in 2021. Ozempic has gained popularity in part due to celebrities using it for weight loss. But there are many concerns with using diabetes drugs for weight loss, including high costs and shortages that are making it harder for people with diabetes to obtain the drugs.

☆ Stocks making the biggest moves after hours: WW International, KeyCorp and more
▼ + stars: | 2023-03-06 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

WW International — Shares jumped more than 6% after WW International, also known as WeightWatchers, said it's acquiring Sequence, a subscription telehealth platform with a focus on chronic weight management, for a net purchase price of $106 million. The deal marks WeightWatchers' foray into a world of clientele who are taking chronic weight management medications, such as glucagon-like peptide 1s. Separately, WW International announced its fourth-quarter and full-year results. Earlier, a CNBC reported that Norfolk Southern is planning to make broad safety adjustments after its third train derailment. KeyCorp — Shares fell about 2% after KeyCorp issued full-year net interest income guidance that was lower than prior guidance, according to an 8-K filing on Monday.

☆ Stock futures are flat as Wall Street awaits Fed Chair Powell's comments: Live updates
▼ + stars: | 2023-03-06 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

U.S. stock futures were little changed on Monday night as traders await Federal Reserve Chair Jerome Powell's latest comments on the state of the economy. Dow Jones Industrial Average futures rose by 11 points, or 0.03%. S&P 500 futures gained 0.06%, while Nasdaq 100 futures dipped 0.06%. Economists polled by Dow Jones expect a decline of 0.4%, compared to a rise of 0.1% in the prior reading. Consumer credit data expected Tuesday afternoon is forecasted to show a rise of $22 billion in January, according to consensus estimates from Dow Jones.

☆ This week's jobs report will help determine if this nascent March rally has legs
▼ + stars: | 2023-03-05 | by ( Zev Fima | ) www.cnbc.com time to read: +6 min

Where the market heads next will once again depend on inflation data — especially this week's highly anticipated jobs report. No portfolio companies report earnings next week. However, with mortgage rates bouncing back in recent weeks, it remains to be seen if the strong monthly report will see any follow up. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ The Fed and a big jobs report could drive the market in the week ahead, as investors watch rates
▼ + stars: | 2023-03-03 | by ( Patti Domm | In | ) www.cnbc.com time to read: +6 min

The seesaw-like tension between interest rates and stock prices should remain in play in the week ahead, as investors focus on comments from Federal Reserve Chairman Jerome Powell and the February employment report. There are few earnings in the week ahead, so economic data will likely be a main driver for stocks, along with the comments from Powell. The futures market is pricing in a high chance for a quarter point, or 25 basis point hike in March. Week ahead calendar Monday Earnings: WW International, ThredUp, Trip.com, Lordstown Motor, Ciena, Grindr 10:00 a.m. Initial claims 10:00 a.m. Fed Vice Chair for Supervision Michael Barr Friday Earnings: Embraer 8:30 a.m. Employment report 2:00 p.m. Federal budget

The Marcy Lab School in Brooklyn, New York, however, has created an alternative path — a one-year program to help students get lucrative tech jobs that typically go to college graduates with a four-year degree. Partnering with the business communityThe Marcy Lab School co-founders Reuben Ogbanna and Bhattacharjee-Marcantonio share ideas at the whiteboard. Tara McCurrie, CNBCThe co-founders worked with the local community to design a program to prepare students for upwardly mobile careers. "We think The Marcy Lab School can scale to thousands of students here in New York City, and potentially have impacts across the country," said Ogbonna. Overcoming degree requirementsDevonte Duncan was part of the orginal class of nine students at the Marcy Lab School in Brooklyn, New York.

☆ WW International Says Chief Financial Officer to Depart
▼ + stars: | 2022-11-30 | by ( Stephen Nakrosis | ) www.wsj.com time to read: 1 min

WW International Inc. on Wednesday said Amy O’Keefe will step down from her role as chief financial officer effective Dec. 2, but will remain with the company through the end of the year to support the finance team. Heather Stark, a 12-year veteran of the company who most recently served as head of North American Finance, will assume the role of interim principal financial officer, the company said. Also on Wednesday, the company, also known as WeightWatchers, said Tiffany Stevenson will join the company in January and assume the role of chief people officer. Most recently, she was chief people officer of Patreon, and before that spent 12 years at Sephora, WW said. The company also appointed David Cohen as chief data officer.

☆ An investor with a $1.8 million portfolio says he sees financial crises as the perfect time to invest in stocks — here's his strategy
▼ + stars: | 2022-11-09 | by ( Leo Ginsburg | Nathan Rennolds | Business Insider Deutschland | ) www.businessinsider.com time to read: +6 min

His total portfolio is worth around $1.8 million. He broke down his investment strategy for Insider and why he saw crises as opportunities. He started investing in the stock market 30 years ago and now has a portfolio worth $1.8 million, he told Insider in an interview. Schäfer told Insider about his investment strategy and how he used financial crises to his advantage. "A nice entry point is when a successful company is experiencing a problem and the stock price halves," Schäfer said.

☆ Oprah Winfrey wants fans to know that she doesn’t endorse weight loss gummies or pills
▼ + stars: | 2022-10-31 | by ( Toyin Owoseje | ) edition.cnn.com time to read: +2 min

CNN —Oprah Winfrey is warning fans against falling victim to companies selling weight loss products using her name and image. On Sunday, the 68-year-old former talk show host and media mogul took to Instagram to distance herself from gummies being sold online, saying she does not endorse edible weight loss products. In the short video, Winfrey said she felt compelled to address the online scams after being approached five times in one week by people looking for weight loss gummies. “I have nothing to do with weight loss gummies or diet pills and I don’t want you all taken advantage of by people misusing my name,” she told her 21.6 million Instagram followers. Please don’t buy any weight loss gummies with my picture or name on them.

☆ The Fed could lay the groundwork for a year end rally in the week ahead
▼ + stars: | 2022-10-28 | by ( Patti Domm | In | ) www.cnbc.com time to read: +8 min

The coming week is also the busiest of the corporate earnings season, with about a third of the S & P 500 companies releasing results. "Historically, the market waits for the last Fed rate hike to be introduced and then the market climbs higher. The S & P 500 was up more than 8.8% for the month. The Dow was up 5.7% on the week, the S & P 500 was up 5.7% and the Nasdaq was up 2.2%. The 50-day moving average is 3,841 for the S & P 500, and it was well above it Friday afternoon for the second time in the past week.

Search resuls for: "WW International"

25 mentions found